Holen Sie sich die Stockscreener-App
5.37
3.50%
-0.195
Schlusskurs vom Vortag:
$5.565
Offen:
$5.5
24-Stunden-Volumen:
30,206
Relative Volume:
1.13
Marktkapitalisierung:
$21.74M
Einnahmen:
$7.44M
Nettoeinkommen (Verlust:
$-56.57M
KGV:
0.1955
EPS:
27.467
Netto-Cashflow:
$-21.40M
1W Leistung:
-9.90%
1M Leistung:
-30.89%
6M Leistung:
-24.58%
1J Leistung:
+0.00%
1-Tages-Spanne:
$5.34
$5.73
1-Wochen-Bereich:
$5.34
$6.34
52-Wochen-Spanne:
$5.34
$9.70
Kyntra Bio Inc Stock (KYNB) Company Profile
Firmenname
Kyntra Bio Inc
Sektor
Branche
Telefon
415-978-1200
Adresse
350 BAY STREET, SAN FRANCISCO
Compare KYNB vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYNB
Kyntra Bio Inc
|
5.37 | 21.74M | 7.44M | -56.57M | -21.40M | 27.47 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kyntra Bio Inc Stock (KYNB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-13 | Eingeleitet | Maxim Group | Buy |
| 2026-07-07 | Eingeleitet | Oppenheimer | Outperform |
| 2026-06-09 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-08-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-26 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | Herabstufung | Stifel | Buy → Hold |
| 2023-06-26 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | Hochstufung | Stifel | Hold → Buy |
| 2023-01-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-09-22 | Herabstufung | Goldman | Neutral → Sell |
| 2021-08-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-07-16 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-03-31 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-03-02 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-26 | Eingeleitet | Raymond James | Underperform |
| 2020-07-10 | Fortgesetzt | Stifel | Buy |
Alle ansehen
Kyntra Bio Inc Aktie (KYNB) Neueste Nachrichten
Kyntra Bio sought Nasdaq review and Kyntra Bio stock costs EUR 5.45 - AD HOC NEWS
Kyntra Bio Faces Nasdaq Delisting, Appeals Listing Decision - The Globe and Mail
Form 4 Kyntra Bio Inc For: 6 October By Investing.com - Investing.com UK
A director receives 14,000 Kyntra Bio (KYNB) stock options with a $6.50 exercise price. - Stock Titan
Kyntra Bio Received Notice of Delisting - TradingView
Form 4 Kyntra Bio Inc For: 6 October By Investing.com - Investing.com Nigeria
Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors - GlobeNewswire Inc.
FibroGen stock trades at USD 6.94 after Kyntra Bio rebrand - AD HOC NEWS
Kyntra Bio (KYNB) CEO reports RSU tax withholding, not a stock sale - Stock Titan
Kyntra Bio (KYNB) CFO holds 4,355 shares after tax withholding - Stock Titan
KIN stock holds steady as Kyntra Bio prepares new earnings update - ad-hoc-news.de
Kyntra Bio to Present at H.C. Wainwright 28th Annual Global Investment Conference - Quiver Quantitative
A drug company's CEO will present in New York Sept. 15. Kyntra Bio will webcast it. - stocktitan.net
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
KYNB Reiterated by HC Wainwright & Co. -- Price Target Maintained at $43 - GuruFocus
Oppenheimer reiterates Kyntra Bio stock rating on debt reduction - Investing.com
Oppenheimer reiterates Kyntra Bio stock rating on debt reduction By Investing.com - Investing.com South Africa
Kyntra Bio Streamlines Financing, Strengthens Balance Sheet - TipRanks
KYNB Looks 65.5% Overvalued on GF Value™ - GuruFocus
Kyntra Bio Cuts Royalty Payments to NQ Project Phoebus for Accelerated Upfront Payment - marketscreener.com
Kyntra Bio Amends Revenue Interest Deal With NQ Project Phoebus, Cuts Cap to $65M, Pays $42.6M - TradingView
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation - marketscreener.com
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation - GlobeNewswire
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation - finance.yahoo.com
Kyntra Bio (KYNB) Edges Higher to $8.02, Up 0.25% as Stock Holds Between Key LevelsSupply Zone - dars.gov.et
Enterprise value to revenue forward of Kyntra Bio, Inc. – BX:KYNB - TradingView
Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript - AOL.com
Kyntra Bio Inc (KYNB) (Q2 2026) Earnings Call Highlights: Advanc - GuruFocus
Kyntra Bio, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:KYNB) 2026-08-16 - Seeking Alpha
Kyntra Bio Confronts Nasdaq Listing Risk as Asset and Revenue Shortfall Threatens Global Select Status - TipRanks
Kyntra Bio, Inc. (NASDAQ: KYNB) Stock Price, News & Analysis - kalkine.ca
Kyntra Bio Inc. (KYNB) Holds Above Key Support After Modest PullbackSector Neutral Pair - vinanet.vn
Kyntra Bio, Inc. (NASDAQ: KYNB) Stock Price, News & Analysis - Kalkine
Armistice Capital (KYNB) discloses 400,000-share, 9.88% Kyntra Bio position - Stock Titan
Kyntra Bio Inc. (KYNB) Holds Above Key Support After Modest PullbackPut Spread Alert - dars.gov.et
Kyntra Bio Inc Q2 Net Income From Cont Ops US - moomoo.com
KYNB Looks 28.4% Overvalued on GF Value™ - GuruFocus
Kyntra Bio Q2 adj. EPS $(4.68) misses $(3.18) estimate - scanx.trade
Kyntra Bio Q2 2026 slides: dual catalysts expected, cash into 2028 - Investing.com
Kyntra Bio Q2 2026 slides: prostate cancer, MDS programs eye Q4 catalysts - Investing.com
Earnings call transcript: Kyntra Bio rises as pipeline updates offset weak Q2 2026 sales - Investing.com
Kyntra Bio Q2 2026 Earnings Call: Complete Transcript - Benzinga
KYNB: Q2 2026 marked clinical progress and a return to profitability, with cash runway into 2028 - TradingView
Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Kyntra Bio, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
KYNTRA BIO ($KYNB) Releases Q2 2026 Earnings - Quiver Quantitative
Is Kyntra Bio Inc (KYNB) Facing Challenges After Q2 Earnings Mis - GuruFocus
Kyntra Bio: Q2 Earnings Snapshot - marketscreener.com
Kyntra Bio: Q2 Earnings Snapshot - aol.com
Kyntra Bio: Q2 Earnings Snapshot - KTVB
Finanzdaten der Kyntra Bio Inc-Aktie (KYNB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kyntra Bio Inc-Aktie (KYNB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Nov 13 '25 |
Buy |
9.18 |
1,000 |
9,180 |
22,239 |
1.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):